satisfied and (43%) not satisfied after treatment.
In this study, the commonest Hamilton Norwoods
scale for males used finasteride and spironolactone
baseline was grade III (37.5%) followed by grade
II and V (18.8%) while commonest Hamilton Nor-
woods scale for males after 6 months was grade
II (43.8%) followed by grade IV and V (12.5%)
No significant statistically significant difference
in between Hamliton Noorwoods scale for male's
baseline and after 6 months using finasteride and
spironolactone. In this study, (100.0%) of the male
group had hair diameter diversity baseline while
(93.8%) had hair diameter diversity after 6 months
treatment. Regarding perpilar sign, all males
(100.0%) had perpilar sign baseline and (81.2%)
had perpilar sign after 6 months treatment. Con-
cerning focal atricha, (93.8%) of the male group
had focal atricha baseline while only (43.8%) had
focal atricha after 6 months treatment seventy five
percent of the female group were satisfied, twelve
and half percent were very satisfied and tweleve
and half percent not satisfied after treatment. In
the this study, Ebling scale (I-IV) of androgenic
alopecia for females: The commonest Ebling scale
for females baseline was grade II (43.8%) follo-
wed by grade IV (25.0%) while commonest Ebling
scale for females after 6 months was grade I
(50.0%) followed by grade II (25.0%) there was
statistically significant difference between Ebling
scale for females' baseline and after 6 months in
female patients. Our study shows that (100.0%) of
the female group had hair diameter diversity base-
line while (93.8%) had hair diameter diversity after
6 months treatment. Regarding perpilar sign,
(93.8%) of the female group had perpilar sign
baseline and (56.3%) had perpilar sign after 6
months treatment. Concerning focal atricha,
(87.5%) of the fe-male group had focal atricha
baseline while only (12.5%) had focal atricha after
6 months treatment.
In our study 68.7% of the male group had
increased hair count after 6 months treatment and
(87.5%) of the female group had increased hair
count after 6 months treatment. There was no
statistically significant difference between male
and female in percent of increased hair count after
treatment.
There was no statistically significant difference
between hair diameter diversity baseline and after
6 months in female patients. There was highly
statistically significant difference between focal
atricha baseline and after 6 months in female
patients. There was statistically significant differ-
ence between Perpilar sign baseline and after 6
months in female patients.
Our study shows that topical spironolactone is
better than topical finasteride in male and female
group.
Topical spironolactone and topical finasteride
in female group were better than topical spironol-
actone and topical finasteride in male group.
Result is in Mazzarella et al., 1997 for evaluat-
ing topical finasteride for pattern hair loss were
found, and only 1 study involved women. Finas-
teride 0.005% (in a base of ethanol, propylene
glycol, and water) was studied in 52 patients with
androgenetic alopecia, including 24 women (mean
age 33 years, range 23-38 years) in a 16-month
single-blind, placebo-controlled trial. Treatment
consisted of 1mL of solution applied twice daily
to balding areas. There was no response to treatment
in the first 3 months, however, by 6 months there
were statistically significant differences in hair
density and hair loss compared to placebo. Although
the results were not stratified by sex, by the end
of the study all treated patients had slight to marked
reduction of balding areas and all reported per-
ceived benefit, rating their treatment moderately
(27%) or highly effective (73%). Treatment was
well-tolerated.
With no report of local or systemic side effects,
and no effect on plasma testosterone or dihydrotes-
tosterone were observed [4] .
These results were in agreement with study
done by Charuwichitratana et al., 2003) using 0.1%
finasteride solution and also in agreement with
another study done by Sitticharoenchai, 2006).
Using 0.5% finasteride solution revealed superior
efficacy to placebo [5,6] .
Also a good response to topical finasteride was
confirmed a systematic seven articles were includ-
ed. In all studies, there was significant increase in
hair density and decrease in the rate of hair loss,
increase total and terminal hair counts, and positive
hair growth assessment with topical FNS. Both
scalp and plasma DHT significantly decreased with
application of topical FNS; no changes in serum
testosterone were noted. The authors concluded
that, preliminary results on the use of topical FNS
are limited, but safe and promising [7] .
A randomized, double-blind, comparative study
to determine the efficacy and safety of 3% minox-
idil versus combined 3% minoxidil/and 0.1% fin-
asteride in male pattern hair loss showed signifi-
cantly greater improvement in the 3% minoxidil/
and 0.1% finasteride group than the minoxidil
group [8] .